Loading patent…
AssigneeIBMsol CO., LTD.
InventorsJongmin KIM, Yunjin KOOK, Aram LEE, Eunsik YUN
Estimating the term…
Provided is a method of diagnosing and treating an endothelial-mesenchymal transition (EndMT)-related disease using SET7/9. It was found that simultaneous treatment of TGF-β2 and IL-1β is a strong inducing condition for endothelial-mesenchymal transition, methyltransferase SET7/9 is an important epigenetic factor in a process of inducing endothelial-mesenchymal transition, and SET7/9 inhibition regulates pro-fibrotic signaling and inhibits endothelial-mesenchymal transition. In addition, it was found that a vascular endothelial cell dysfunction caused by endothelial-mesenchymal transition was restored by the SET7/9 inhibition and the endothelial-mesenchymal transition was closely related to a pulmonary vascular disease.
A biomarker composition for diagnosing an endothelial-mesenchymal transition (EndMT)-related disease, the biomarker composition comprising methyltransferase SET7/9 protein or a gene encoding methyltransferase SET7/9 protein as an active ingredient.
A composition for diagnosing an EndMT-related disease, the composition comprising an agent capable of measuring an expression level of methyltransferase SET7/9 as an active ingredient.
6-10. (canceled)
A pharmaceutical composition for preventing or treating pulmonary arterial hypertension, the pharmaceutical composition comprising a SET7/9 expression or activity inhibitor as an active ingredient.
(canceled)
15-16. (canceled)
Dependencies are inferred from the claim text.